DOCETAXEL-INDUCED FEBRILE NEUTROPENIA IN BREAST CANCER PATIENTS IN MALAYSIA
Received 2020-10-25; Accepted 2021-09-11; Published 2021-10-11
Keywords:Advanced breast cancer, Chemotherapy, Docetaxel, Febrile neutropenia
Docetaxel induced febrile neutropenia (FN) is a common adverse event encountered by breast cancer patients worldwide, especially among Asian patients. We aim to evaluate incidence of FN in breast cancer patients receiving docetaxel in Malaysia.
We retrospectively reviewed the records from patients with breast cancer who received docetaxel in a university-hospital. The incidence of FN, length of hospital stay, incidence of ICU admission, incidence and grade of neutropenia were evaluated.
Among 237 breast cancer patients, incidence of FN was 14.34% (34 patients). Mean length of hospital stay was 9.28 days (2 to 94 days). Two patients (0.84%) required admission to the ICU with the length of stay being 4 and 60 days respectively. Incidences of neutropenia are 27.8% (grade 1), 0.8% (grade 2), 1.69% (grade 3) and 0.4% (grade 4).
The incidence of febrile neutropenia due to docetaxel was higher among this population. This data may help to determine the optimal dose of docetaxel in breast cancer patients.
All authors agree that the article, if editorially accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0 to allow others to freely access, copy and use research provided the author is correctly attributed, unless otherwise stated. All articles are available online without charge or other barriers to access. However, anyone wishing to reproduce large quantities of an article (250+) should inform the publisher. Any opinion expressed in the articles are those of the authors and do not reflect that of the University of Malaya, 50603 Kuala Lumpur, Malaysia.